{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:05:20Z","timestamp":1793858720223,"version":"4.6.1"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2011,3,8]],"date-time":"2011-03-08T00:00:00Z","timestamp":1299542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Learning Objectives<\/jats:title>\n                    <jats:p>After completing this course, the reader will be able to: Evaluate early data regarding the impact of daily vaginal testosterone on estradiol and testosterone levels in breast cancer patients receiving treatment with aromatase inhibitors.Explain the potential clinical benefits of vaginal testosterone therapy to treat vaginal atrophy in women with breast cancer receiving long-term aromatase inhibitor therapy.<\/jats:p>\n                    <jats:p>This article is available for continuing medical education credit at CME.TheOncologist.com<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose.<\/jats:title>\n                    <jats:p>Controversy exists about whether vaginal estrogens interfere with the efficacy of aromatase inhibitors (AIs) in breast cancer patients. With the greater incidence of vaginal atrophy in patients on AIs, a safe and effective nonestrogen therapy is necessary. We hypothesized that vaginal testosterone cream could safely treat vaginal atrophy in women on AIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>Twenty-one postmenopausal breast cancer patients on AIs with symptoms of vaginal atrophy were treated with testosterone cream applied to the vaginal epithelium daily for 28 days. Ten women received a dose of 300 \u03bcg, 10 received 150 \u03bcg, and one was not evaluable. Estradiol levels, testosterone levels, symptoms of vaginal atrophy, and gynecologic examinations with pH and vaginal cytology were compared before and after therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Estradiol levels remained suppressed after treatment to &amp;lt;8 pg\/mL. Mean total symptom scores improved from 2.0 to 0.7 after treatment (p &amp;lt; .001) and remained improved 1 month thereafter (p = .003). Dyspareunia (p = .0014) and vaginal dryness (p &amp;lt;.001) improved. The median vaginal pH decreased from 5.5 to 5.0 (p = .028). The median maturation index rose from 20% to 40% (p &amp;lt; .001). Although improvement in total symptom score was similar for both doses (\u22121.3 for 300 \u03bcg, \u22120.8 for 150 \u03bcg; p = .37), only the 300-\u03bcg dose was associated with improved pH and maturation values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>A 4-week course of vaginal testosterone was associated with improved signs and symptoms of vaginal atrophy related to AI therapy without increasing estradiol or testosterone levels. Longer-term trials are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2010-0435","type":"journal-article","created":{"date-parts":[[2011,3,8]],"date-time":"2011-03-08T21:10:17Z","timestamp":1299618617000},"page":"424-431","source":"Crossref","is-referenced-by-count":137,"title":["Topical Testosterone for Breast Cancer Patients with Vaginal Atrophy Related to Aromatase Inhibitors: A Phase I\/II Study"],"prefix":"10.1093","volume":"16","author":[{"given":"Sabrina","family":"Witherby","sequence":"first","affiliation":[{"name":"a Warren Alpert School of Medicine at Brown University, Providence, Rhode Island, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Johnson","sequence":"additional","affiliation":[{"name":"b University of Massachusetts Medical School, Worcester, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Demers","sequence":"additional","affiliation":[{"name":"c Hershey Medical Center, Pennsylvania State University, Hershey, Pennsylvania, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Mount","sequence":"additional","affiliation":[{"name":"d University of Vermont, Burlington, Vermont, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Littenberg","sequence":"additional","affiliation":[{"name":"d University of Vermont, Burlington, Vermont, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D.","family":"Maclean","sequence":"additional","affiliation":[{"name":"d University of Vermont, Burlington, Vermont, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Wood","sequence":"additional","affiliation":[{"name":"d University of Vermont, Burlington, Vermont, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyman","family":"Muss","sequence":"additional","affiliation":[{"name":"e University of North Carolina Medical School, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,3,8]]},"reference":[{"key":"2021122303325882400_B1","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/00001813-200409000-00003","article-title":"Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients","volume":"15","author":"Morales","year":"2004","journal-title":"Anticancer Drugs"},{"key":"2021122303325882400_B2","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2004.08.029","article-title":"Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial","volume":"22","author":"Fallowfield","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122303325882400_B3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/13697130500487224","article-title":"Menopausal symptoms in women treated for breast cancer: The prevalence and severity of symptoms and their perceived effects on quality of life","volume":"9","author":"Gupta","year":"2006","journal-title":"Climacteric"},{"issue":"4","key":"2021122303325882400_B4","doi-asserted-by":"publisher","first-page":"CD001500","DOI":"10.1002\/14651858.CD001500.pub2","article-title":"Local oestrogen for vaginal atrophy in postmenopausal women","author":"Suckling","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl","key":"2021122303325882400_B5","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/0378-5122(95)00960-4","article-title":"Estrogen therapy in the management of problems associated with urogenital ageing: A simple diagnostic test and the effect of the route of hormone administration","volume":"22","author":"Notelovitz","year":"1995","journal-title":"Maturitas"},{"key":"2021122303325882400_B6","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/annonc\/mdj127","article-title":"Estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors","volume":"17","author":"Kendall","year":"2006","journal-title":"Ann Oncol"},{"key":"2021122303325882400_B7","volume-title":"Effects of serum estradiol levels in postmenopausal breast cancer survivors taking an aromatase inhibitor of selective estrogen receptor modulator [abstract 806]","author":"Wills","year":"2009"},{"key":"2021122303325882400_B8","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/jcp.55.6.446","article-title":"The effect of Replens\u00ae on vaginal cytology in the treatment of postmenopausal atrophy: Cytomorphology versus computerised cytometry","volume":"55","author":"Van der Laak","year":"2002","journal-title":"J Clin Pathol"},{"key":"2021122303325882400_B9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0015-0282(16)56474-7","article-title":"Comparative study: Replens\u00ae versus local estrogen in menopausal women","volume":"61","author":"Nachtigall","year":"1994","journal-title":"Fertil Steril"},{"key":"2021122303325882400_B10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1089\/jwh.1994.3.427","article-title":"Treating vaginal dryness in breast cancer patients: Results of applying a polycarbophil moisturizing gel","volume":"3","author":"Gelfand","year":"1994","journal-title":"J Womens Health"},{"key":"2021122303325882400_B11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1530\/acta.0.0040265","article-title":"Proliferative effect of testosterone propionate on human vaginal epithelium","volume":"4","author":"Salinger","year":"1950","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2021122303325882400_B12","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer","volume":"348","author":"Smith","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122303325882400_B13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1210\/er.2003-0016","article-title":"Testosterone effects on the breast: Implications for testosterone therapy for women","volume":"25","author":"Somboonporn","year":"2004","journal-title":"Endocr Rev"},{"issue":"suppl 1","key":"2021122303325882400_B14","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.maturitas.2005.06.014","article-title":"Management of post-menopausal vaginal atrophy and atrophic vaginitis","volume":"52","author":"Castelo-Branco","year":"2005","journal-title":"Maturitas"},{"key":"2021122303325882400_B15","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1210\/jc.2004-1747","article-title":"Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder","volume":"90","author":"Simon","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122303325882400_B16","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/archinte.165.14.1582","article-title":"Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial","volume":"165","author":"Braunstein","year":"2005","journal-title":"Arch Intern Med"},{"key":"2021122303325882400_B17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003495-199855020-00006","article-title":"Transdermal testosterone","volume":"55","author":"McClellan","year":"1998","journal-title":"Drugs"},{"key":"2021122303325882400_B18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0002-9378(96)70444-1","article-title":"Delivery of dehydroepiandrosterone to premenopausal women: Effects of micronization and nonoral administration","volume":"174","author":"Casson","year":"1996","journal-title":"Am J Obstet Gynecol"},{"key":"2021122303325882400_B19","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1056\/NEJM200009073431002","article-title":"Transdermal testosterone treatment in women with impaired sexual function after oophorectomy","volume":"343","author":"Schifren","year":"2000","journal-title":"N Engl J Med"},{"key":"2021122303325882400_B20","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"2021122303325882400_B21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1210\/jcem-68-1-99","article-title":"Inhibition of aromatase with CGS 16949A in postmenopausal women","volume":"68","author":"Santen","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122303325882400_B22","first-page":"3007","article-title":"To block estrogen's synthesis or action: That is the question","volume":"87","author":"Santen","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122303325882400_B23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0960-0760(95)00045-2","article-title":"Arimidex: A new oral, once-a-day aromatase inhibitor","volume":"53","author":"Plourde","year":"1995","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2021122303325882400_B24","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1002\/1097-0142(19950415)75:8<2132::AID-CNCR2820750816>3.0.CO;2-U","article-title":"Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer","volume":"75","author":"Lipton","year":"1995","journal-title":"Cancer"},{"key":"2021122303325882400_B25","first-page":"823","article-title":"Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms","volume":"102","author":"Speroff","year":"2003","journal-title":"Obstet Gynecol"},{"key":"2021122303325882400_B26","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1067\/mob.2003.23","article-title":"Are women with urogenital atrophy symptomatic?","volume":"188","author":"Davila","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"2021122303325882400_B27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00042192-200007030-00005","article-title":"17\u03b2-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis","volume":"7","author":"Rioux","year":"2000","journal-title":"Menopause"},{"key":"2021122303325882400_B28","first-page":"225","article-title":"Cytologic evaluation of the effect of various estrogens given in postmenopause","volume":"21","author":"Hustin","year":"1977","journal-title":"Acta Cytol"},{"key":"2021122303325882400_B29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2307\/3001968","article-title":"Individual comparisons by rank methods","volume":"1","author":"Wilcoxon","year":"1945","journal-title":"Biometrics"},{"key":"2021122303325882400_B30","volume-title":"A phase II study of vaginal testosterone cream (TEST) vs. Estring for vaginal dryness or decreased libido in women with early stage breast cancer (BC) treated with aromatase inhibitors (AIs) [abstract 5038[rsqb]","author":"Melisko","year":"2009"},{"key":"2021122303325882400_B31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0378-5122(94)00863-3","article-title":"The vaginal epithelium in the postmenopause- cytology, histology and pH as methods of assessment","volume":"21","author":"Nilsson","year":"1995","journal-title":"Maturitas"},{"key":"2021122303325882400_B32","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/gme.0b013e31819e8e2d","article-title":"Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy","volume":"16","author":"Labrie","year":"2009","journal-title":"Menopause"},{"key":"2021122303325882400_B33","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/gme.0b013e31819e8930","article-title":"Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration","volume":"16","author":"Labrie","year":"2009","journal-title":"Menopause"},{"key":"2021122303325882400_B34","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/j.1743-6109.2009.01667.x","article-title":"A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women","volume":"7","author":"Raghunandan","year":"2010","journal-title":"J Sex Med"},{"key":"2021122303325882400_B35","volume-title":"U.S. National Institutes of Health"},{"key":"2021122303325882400_B36","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/gme.0b013e31819e85c6","article-title":"Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women","volume":"16","author":"Labrie","year":"2009","journal-title":"Menopause"},{"key":"2021122303325882400_B37","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3109\/09513590903511547","article-title":"High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy","volume":"26","author":"Labrie","year":"2010","journal-title":"Gynecol Endocrinol"},{"key":"2021122303325882400_B38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1158\/1055-9965.EPI-08-0808","article-title":"Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: The ORDET cohort","volume":"18","author":"Sieri","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021122303325882400_B39","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1093\/jnci\/djj376","article-title":"Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women","volume":"98","author":"Eliassen","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"2021122303325882400_B40","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/jnci\/djm062","article-title":"Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women","volume":"99","author":"Tamimi","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2021122303325882400_B41","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/jnci\/90.17.1292","article-title":"Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women","volume":"90","author":"Hankinson","year":"1998","journal-title":"J Hatl Cancer Inst"},{"key":"2021122303325882400_B42","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/oxfordjournals.aje.a009059","article-title":"Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women","volume":"145","author":"Zeleniuch-Jacquotte","year":"1997","journal-title":"Am J Epidemiol"},{"key":"2021122303325882400_B43","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ijc.20582","article-title":"Serum testosterone levels and breast cancer recurrence","volume":"113","author":"Berrino","year":"2005","journal-title":"Int J Cancer"},{"key":"2021122303325882400_B44","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/1055-9965.EPI-07-0761","article-title":"Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer","volume":"17","author":"Rock","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021122303325882400_B45","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1111\/j.1743-6109.2009.01289.x","article-title":"The incidence of invasive breast cancer among women prescribed testosterone for low libido","volume":"6","author":"Davis","year":"2009","journal-title":"J Sex Med"},{"key":"2021122303325882400_B46","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1258\/mi.2008.008015","article-title":"Testosterone and the breast","volume":"14","author":"Shufelt","year":"2008","journal-title":"Menopause Int"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2010-0435","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2010-0435","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/4\/424\/41853676\/oncolo_16_4_424.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/4\/424\/41853676\/oncolo_16_4_424.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:31:52Z","timestamp":1640219512000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/16\/4\/424\/6400838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,8]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2011,3,8]]},"published-print":{"date-parts":[[2011,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2010-0435","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.9767956.10460054","asserted-by":"object"}]},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,4,1]]},"published":{"date-parts":[[2011,3,8]]}}}